Evidence map›Paper›PMID 40332355›Full record

ArticleInternational journal of molecular sciences2025

Surface Plasmon Resonance (SPR) for the Binding Kinetics Analysis of Synthetic Cannabinoids: Advancing CB1 Receptor Interaction Studies.

Xuesong Shi, Lixin Kuai, Deli Xu, Yanling Qiao, Yuanyuan Chen, Bin Di, Peng Xu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuesong ShiSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Lixin KuaiSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Deli XuSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Yanling QiaoSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Yuanyuan ChenSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Bin DiSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Peng XuChina Pharmaceutical University Joint Laboratory on Key Technologies of Narcotics Control, Office of China National Narcotics Control Commission, Beijing 100193, China.

Funding

National Key Research and Development Program 2022YFC3300905
6 · The paper itself

Abstract

Synthetic cannabinoids (SCs), a class of widely abused new psychoactive substances, are characterized by their structural diversity and rapid evolution. Structure-affinity relationships are crucial for predicting pharmacological effects and potential toxicity. Traditional methods for affinity testing are often complex and less applicable to newly modified compounds. In contrast, Surface Plasmon Resonance (SPR) is a sensitive and label-free technology that detects molecular interactions by measuring refractive index changes on a metallic surface with the advantages of high sensitivity, low sample consumption, and high-throughput capability. In this study, we used SPR to determine the receptor affinity constants of 10 SCs, including some first-reported substances, and analyzed their structure-affinity relationships to validate the method's reliability. The results showed that (1) indazole-based SCs exhibited stronger CB1 receptor affinity compared to their indole counterparts, (2) the head structure of p-fluorophenyl enhanced affinity relative to 5-fluoropentyl, (3) and the affinity rankings obtained from SPR experiments were consistent with those derived from traditional methods. These results collectively demonstrate the reliability and effectiveness of SPR in assessing CB1 receptor affinity and differentiating affinity differences among structurally similar analogs, with promising application prospects in drug research, particularly in the development and screening of therapeutic agents targeting cannabinoid receptors.

Indexed as

CannabinoidsReceptor, Cannabinoid, CB1Surface Plasmon ResonanceHumansKineticsProtein BindingStructure-Activity RelationshipCannabinoidsReceptor, Cannabinoid, CB1CB1 receptor affinitySurface Plasmon Resonance technologysynthetic cannabinoids

Identifiers

PMID40332355
PMCPMC12027443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.